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In this study, a simple and accurate high-performance liquid chromatography method
was developed and validated for fast separation of three anti-glaucoma drugs: timolol
maleate (TM), brimonidine tartrate (BM), and latanoprost (LP). Separation of the three
drugs was achieved in < 6 minutes using a BDS Hypersil phenyl column and a
mobile phase consisting of acetonitrile: 25mM phosphate buffer, pH 4.0 (50: 50, v/v) at
1.2 mL/min with UV detection at 210 nm. The method was linear over the concentration
ranges of 5.0e200.0 mg/mL, 2.0e80.0 mg/mL and 1.0e25.0 mg/mL with lower detection
limits of 0.21 mg/mL, 0.10 mg/mL and 0.11 mg/mL for TM, BM and LP, respectively. The
method was applied for the determination of two fixed-dose combination eye drops for
the treatment of glaucoma, containing TM together with either BM or LP. Commercial
samples of single-ingredient ophthalmic solutions containing the studied drugs were
also successfully analyzed. The results obtained by the proposed method were favorably
compared with those obtained by the comparison methods using Student's t test and the
variance ratio F test.
Copyright © 2016, Food and Drug Administration, Taiwan. Published by Elsevier Taiwan
LLC. This is an open access article under the CC BY-NC-ND license (http://
creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
Glaucoma is a neurodegenerative ocular disorder associated
with distinct changes in the optic nerve head and retinal nerve
fiber layer. An increase in the number of patients with glau-
coma to ~80 million by 2020 is expected by the World Health
Organization [1]. At present, many therapeutic options have
been adopted for the treatment of glaucoma, including se-
lective and nonselective b-blockers, carbonic anhydrase in-
hibitors, prostaglandin analogs, adrenergic agonists, andlytical Chemistry, Faculty
(R. El-Shaheny).
inistration, Taiwan. Publis
/licenses/by-nc-nd/4.0/).cholinergic agonists. Among the different drugs for the
treatment of glaucoma, timolol maleate (TM), brimonidine
tartrate (BM), and latanoprost (LP) are commonly adminis-
tered either as a single agent or as combined therapy [2].
TM is defined chemically as 2-propanol, 1-(1,1-
dimethylethyl)amino-3-[[4-(4-morpholinyl)-1,2,5-thiadiazole-
3-yl]-,(S)-, (Z)-2-butenedioate (1:1) (salt)). TM is a non-
cardioselective b-blocker without intrinsic sympathomimetic
or membrane-stabilizing action. It treats glaucoma by inhibi-
tion of b-adrenergic receptors in the ciliary epithelium andof Pharmacy, University of Mansoura, Mansoura 35516, Egypt.
hed by Elsevier Taiwan LLC. This is an open access article under the CC
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imidazolin-2-ylamino) quinoxaline D-tartrate, is an a2-adre-
noceptor agonist that decreases the intraocular pressure by
reducing the production of aqueous humor [3], while LP (iso-
propyl(Z)-7-{(1R,2R,3R,5S)-3,5-dihydroxy-2-[(3R)-3-hydroxy-5-
phenyl-pentyl]cyclopentyl}-5-heptenoate), is a synthetic
prostaglandin F2a analog that lowers the intraocular pressure
by increasing the uveoscleral outflow [3]. The combined
therapy of TM with either BM or LP is effective for manage-
ment of glaucoma and ocular hypertension [3]. The structural
formulas of the three compounds are presented in Fig. 1.
The United States Pharmacopoeia [4] and the British
Pharmacopoeia [5] recommend titrimetric methods for TM
determination in pure form with acetous perchloric acid as a
titrant and potentiometric detection of the end point. TheN
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Fig. 1 e Structural formulas of the studied drugs.United States Pharmacopoeia [4] determined it in tablets and
eye drops using HPLC methods, while the British Pharmaco-
poeia [5] described direct spectrophotometric assay for it in
tablets and eye drops, and HPLC for its combination eye drops
with dorzolamide. A number of analytical methods deter-
mined TM either alone or with other drugs including; spec-
trophotometry [6e9], high-performance thin layer
chromatography (HPTLC) [10], liquid chromatography (LC)
[11e19], and capillary electrophoresis [20]. For BM, it was
determined by some analytical methods such as spectropho-
tometry [21e23], spectrofluorimetry [23], LC [24e26], gas
chromatography/mass spectrometry [27], and capillary elec-
trophoresis [28]. As for LP, few analytical methods have been
published for its determination, such as HPLC [29].
Some analytical methods are available for the assay of
coformulated ophthalmic solutions containing TM/BM or TM/
LP mixtures. LC [30e32], spectrophotometry [32e34], and
HPTLC [35] methods are reported for the simultaneous assay
of TM and BM in eye drops. Some HPLC methods [36e38] are
also reported for the determination of TM/LP mixtures. These
methods have some weaknesses such as poor sensitivity
[30,31,33e37], narrow linearity ranges [30,31,33e35,38], poor
column efficiency [32], and need for time-programmed UV
detection [32,37,38], column-temperature control [37], or
gradient elution [38].
Hence, we initiated the present study to develop and vali-
date a simple, rapid and sensitive HPLC method for the sep-
aration and quantification of TM, BM and LP. Simultaneous
assay of the commonly prescribed anti-glaucoma drugs using
the same separation conditions is suitable for routine phar-
maceutical analysis in quality control laboratories.2. Materials and Methods
2.1. Instrumentation
The HPLC system (Shimadzu Corporation, Kyoto, Japan) was
fitted with an LC-20AD chromatograph, a Rheodyne injector
valve with 20-mL sample loop, a SPD-20A UV-Visible detector,
and a DGU-20A5 online solvent degasser. The instrument was
interfaced to a computer for data acquisition with a CBM-20A
communication bus module. A Consort P-901 pH-meter
(Turnhout, Belgium) and a Sonix IV SS 101 H 230 ultrasonic
bath (Charleston, SC, USA) were used.2.2. Chemicals and reagents
TM (batch #TML0334201205) and BM (batch #RK12BRT007)
pure samples were gifts from EIPICO (Tenth of Ramadan City,
Egypt). LP pure solution (10.0 mg oil) was purchased from
Tokyo Chemical Industries (Tokyo, Japan). Purities of the
samples were found to be 99.45%, 100.18% and 99.25% for TM,
BM and LP, respectively, as determined by the comparison
methods [30,36]. Maleic acid (99.0%) and potassium dihy-
drogen phosphate were obtained from Adwic (Cairo, Egypt).
Acetonitrile and methanol (HPLC grade) were purchased from
SigmaeAldrich (St. Louis, MO, USA). Orthophosphoric acid
(85%, w/v) was obtained from Riedel-deH€aen (Seelze,
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Fig. 2 e Representative chromatogram for the separation of
timolol maleate (150.0 mg/mL), brimonidine tartrate
(60.0 mg/mL), and latanoprost (5.0 mg/mL) in laboratory-
prepared mixture.
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membrane filter was used in this study.
2.3. Pharmaceutical samples
The following pharmaceutical formulations were purchased
from Egyptian pharmacies: Combigan eye drops (labeled to
contain 2 mg/mL BM þ 5 mg/mL timolol equivalent to 6.8 mg/
mL TM) (Allergan Pharmaceuticals, Westport, Ireland); Xala-
com eye drops (labeled to contain 50 mg/mL LP þ 5 mg/mL
timolol equivalent to 6.8 mg/mL TM) (Pfizer Manufacturing,
Belgium); Timolol eye drops (labeled to contain 0.5% timolol
equivalent to 0.68% TM) (EIPICO); Alphagan eye drops (labeled
to contain 0.15% BM) (Allergan Pharmaceuticals); and Ioprost
eye drops (labeled to contain 50 mg/mL LP) (Orchidia Pharma-
ceuticals, Cairo, Egypt).
2.4. HPLC conditions
A BDS Hypersil phenyl column (4.6 mm  250 mm, 5-mm
particle size), from Thermo Electron Corporation (Runcorn,
UK), was used with a mobile phase consisting of acetonitrile
and 25mM phosphate buffer, pH 4.0, in the ratio of 50:50, v/v.
The mobile phase was filtered with a 0.45-mm Millipore
membrane filter and degassed by sonication for 30 minutes
before pumping at 1.2 mL/min. UV detection was set at
210 nm.
2.5. Standard solutions
An amount of 20.0 mg TM and BM were individually weighed,
transferred to 100-mL volumetric flasks, and dissolved in
methanol. The volumes were completed to the mark with the
same solvent to prepare the standard solutions (200.0 mg/mL).
LP pure solution was diluted with methanol to obtain a stan-
dard solution with a concentration of 100.0 mg/mL. The stan-
dard solutions were stable for at least 7 days when kept in a
refrigerator at 4C.
2.6. Calibration graphs
The standard solutions of the studied drugs were diluted with
the mobile phase to prepare working solutions containing
5.0e200.0 mg/mL, 2.0e80.0 mg/mL and 1.0e25.0 mg/mL TM, BM
and LP, respectively. The solutionswerewell mixed, and 20-mL
injections were made in triplicate and eluted under the opti-
mum chromatographic conditions. The calibration graphs
were obtained by plotting the average peak areas of each drug
versus the corresponding concentrations and the regression
equations were derived.
2.7. Analysis of laboratory-prepared mixtures of TM/BM
and TM/LP
Laboratory-prepared mixtures containing TM/BM and TM/LP
mixtures in the recommended pharmaceutical ratios of 6.8:2
and 136:1, respectively (as in their coformulated eye drops),
were prepared in the mobile phase. Triplicate 20-mL injections
of each solutionweremade. The average percentage found foreach drugwas determined using the corresponding regression
equation.2.8. Analysis of ophthalmic solutions
One milliliter of each eye drop formulation was transferred to
10-mL volumetric flasks and diluted to a final volume with
high-purity water. Appropriate volumes of each eye drop so-
lution were transferred into a set of 10-mL volumetric flasks
and made up to the final volume with the mobile phase. So-
lutions were well mixed, triplicate 20-mL injections were
made, and eluted under the optimum chromatographic con-
ditions. The nominal concentration of each drug was calcu-
lated from the regression equation.3. Results
3.1. Method development and optimization
Different chromatographic conditions were studied for sepa-
ration of TM, BM and LP. The most important aspects in HPLC
method development are the achievement of good resolution
and peak symmetry in a reasonable analysis time with
appropriate sensitivity. Detection wavelength, mobile phase
composition, pH, and flow ratewere carefully optimized. Good
separation of TM, BM, LP and maleic acid, which is the salt
part of TM, was attained within a short run time (< 6 minutes)
using a mobile phase consisting of acetonitrile: 25mM phos-
phate buffer, pH 4.0, (50:50, v/v) at 1.2 mL/min with UV
detection at 210 nm. Fig. 2 illustrates a typical chromatogram
for the separation of the three analytes, where LP, TM and BM
were eluted at 3.1, 4.1 and 4.9 minutes, respectively, without
interference from maleic acid (tR ¼ 2.1 min).3.2. Method validation
Validation procedure was carried out according to Interna-
tional Conference on Harmonization (ICH) Guidelines [39].
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To establish the linearity of the proposed method, calibration
graphs were constructed using sets of standard solutions at
seven concentration levels for each drug. The data were
statistically analyzed [40] and the results are illustrated in
Table 1.
3.2.2. Limits of quantification and detection
Limit of quantification and limit of detection were calculated
according to ICH Guidelines [39] using the method of standard
deviation (SD) of the intercept of the regression line and the
slope. Table 1 illustrates the obtained results.
3.2.3. Accuracy
The developed method was tested for the accuracy by
analyzing pure samples of TM, BM and LP in triplicate over the
working concentration ranges of 5.0e200.0 mg/mL, 2.0e80.0 mg/
mL and 1.0e25.0 mg/mL, respectively (n ¼ 7 for each com-
pound). The average percentage found (± SD) were
100.26 ± 1.20%, 100.51 ± 1.51% and 100.09 ± 1.31% for TM, BM
and LP, respectively. The results were compared with those
obtained using the comparisonmethods [30,36] (99.45 ± 1.25%,
100.18 ± 1.02% and 99.25 ± 0.85% for TM, BM and LP, respec-
tively) by applying Student's t test and the variance ratio F test
[40]. In all cases, the calculated t and F values were lower than
the tabulated values.
3.2.4. Precision
Intra-day precision was tested by the analysis of three con-
centrations of each compound three times within the same
day. Inter-day precisionwas also considered by the analysis of
three concentrations of each compound in three successive
days. The results of precision study are shown in Table 2.
3.2.5. Selectivity
The selectivity of the method was tested by the analysis of
laboratory-prepared mixtures of the studied drugs in theTable 1 e Collective calibration data for the studied drugs
by the proposed method.
Parameter TM BM LP
Concentration range
(mg/mL)
5.0e200.0 2.0e80.0 1.0e25.0
Limit of detection (mg/mL)a 0.21 0.10 0.06
Limit of quantification
(mg/mL)b
0.65 0.29 0.19
Correlation coefficient (r) 0.9999 0.9999 0.9999
Slope 9.64  103 6.51  104 3.97  103
Intercept 3.93  104 3.70  104 966
Standard deviation of
the residuals (Sy/x)
4.03  103 1.23  104 261
Standard deviation of
the intercept (Sa)
622 1.90  103 77
Standard deviation of
the slope (Sb)
23.97 183.30 11.92
%RSD 1.19 1.50 1.31
% Error 0.45 0.57 0.50
BM ¼ brimonidine tartrate; LP ¼ latanoprost; TM ¼ timilol maleate.
a 3.3Sa/b, where b ¼ the slope of the regression line.
b 10Sa/b, where b ¼ the slope of the regression line.ratios of 6.8:2 and 136:1 for TM/BM and TM/LP, respectively.
The average percentages found ± SD for TM and BM in their
mixture were 100.14 ± 0.28% and 100.44 ± 0.70%, respectively,
and those for TM and LP in their mixture were 100.12 ± 0.34%
and 100.66 ± 0.94%, respectively.
3.2.6. Robustness
To prove the robustness of the method, small changes were
made in the percentage of acetonitrile (50 ± 1%, v/v), molar
concentration of phosphate buffer (25 ± 1mM) and the flow
rate (1.2 ± 0.1 mL/min). No significant changes in theoretical
plates count (NTP), resolution factor (Rs), or tailing factor (T)
were observed under these conditions.
3.2.7. System suitability testing
System suitability parameters were evaluated so as to prove
the system performance using working solutions of TM, BM
and LP. Parameters including NTP, Rs and T were calculated
and illustrated in Table 3.
3.3. Pharmaceutical application
Applicability of the method was confirmed by the analysis of
commercially available coformulated ophthalmic solutions
containing fixed-dose combinations of TM/BM and TM/LP
(Table 4). Additionally, single-component ophthalmic solu-
tions containing the three compounds were analyzed (Table
4). Fig. 3 shows typical chromatograms for the determina-
tion of the three drugs in different ophthalmic solutions.4. Discussion
4.1. Method development and optimization
For the choice of optimum detection wavelength, different
wavelengths were investigated (210, 254 and 295 nm). LP is a
weak UV-absorbing compound that exhibits considerable
absorbance only in the middle UV region. In addition, it exists
in low concentration in formulation (50 mg/mL eye drops). As a
consequence, 210 nm was a suitable wavelength to record all
chromatograms to quantify TM, BM and LP simultaneously. At
thiswavelength,maleic acid, which represents the saltmoiety
of TM, was detected. The identity of maleic acid was
confirmed by injection of pure maleic acid solution where it
appeared at the same retention time (tR¼ 2.1min). In contrast,
the salt part of BM (tartaric acid) is undetectable at this
wavelength because it has a sharp cutoff of < 210 nm [41].
Several mobile phases were tested using various pro-
portions of different aqueous phases and organic modifiers.
Methanol and acetonitrile were tried as organicmodifiers, and
water and phosphate buffer were investigated as aqueous
phases.When usingmobile phases containingmethanol as an
organic modifier or water as an aqueous phase, the chro-
matographic peaks showed increased retention in addition to
poor resolution. A mobile phase composed of acetonitrile and
phosphate buffer was selected in further studies.
The ratio of acetonitrile in the mobile phase was studied
over the range of 40e65%, v/v. Increasing the concentration of
acetonitrile by > 50%, v/v leads to inadequate separation of TM
Table 2 e Precision data for the three studied drugs by the proposed method.
Compound Concentration (mg/mL) Intra-day precision Inter-day precision
% found ± SD % RSD % Error % found ± SD % RSD % Error
TM 5.0 100.79±1.03 1.03 0.59 100.10±1.25 1.25 0.72
25.0 99.79±1.44 1.45 0.84 98.84±1.39 1.40 0.81
100.0 100.12±1.14 1.14 0.66 100.17±1.35 1.35 0.78
BM 2.0 100.50±0.88 0.87 0.51 99.46±1.33 1.33 0.77
15.0 101.17±1.26 1.25 0.72 99.13±1.44 1.45 0.84
40.0 101.51±0.74 0.72 0.42 100.46±1.33 1.32 0.76
LP 1.0 100.84±0.62 0.61 0.35 100.80±0.87 0.86 0.50
10.0 101.46±0.68 0.67 0.38 100.13±0.35 0.35 0.20
20.0 100.80±1.33 1.33 0.76 99.46±0.87 0.87 0.51
BM ¼ brimonidine tartrate; LP ¼ latanoprost; RSD ¼ relative standard deviation; SD ¼ standard deviation; TM ¼ timilol maleate.
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acetonitrile in the mobile phase was kept at 50%, v/v to ach-
ieve the best separation within a short time.
The ionic strength of phosphate buffer was also investi-
gated over the concentration range of 10e50mM. With buffer
concentrations < 25mM, TM and BM showed peak broadening
and increased retention times, whereas, using buffer solu-
tions of concentrations > 25mM resulted in poor resolution
between the three drugs. Phosphate buffer at 25mM was
finally selected as the optimum concentration.
Furthermore, the pH of phosphate buffer was studied over
the range of 3.0e6.5. It was observed that the change in the pH
of the buffer solution had an insignificant effect on the reten-
tion of the three compounds. This behavior was probably due
to thehighpKa of the three compounds (pKa¼ 9.21, 7.4 [30], and
14.47 [42] for TM, BM and LP, respectively). So, the three com-
pounds are in the cationic forms over the working pH range.
Eventually, phosphatebuffer at pH4.0wasused in this study to
maintain the durability and lifetime of the column.
For the flow rate optimization, it was studied over the
range of 0.8e1.2 mL/min. For rapid routine analysis, a flow
rate of 1.2 mL/min was adopted, allowing a total chromato-
graphic run of < 6minutes, with good resolution of the studied
compounds.
It is well known that the selectivity of phenyl column
differs from that of the alkyl-silica columns. The retention on
phenyl column increases as the pep interactions of theTable 3 e Final system suitability test parameters for the
proposed method.a.
Compound No. of theoretical
plates (NTP)
Tailing factor (T)
TM 2574 1.40
BM 2610 1.47
LP 2780 1.23
Compounds Resolution (Rs)
b
Maleic acid/LP 1.81
LP/TM 3.35
TM/BM 1.75
BM ¼ brimonidine tartrate; LP ¼ latanoprost; TM ¼ timilol maleate.
a Calculations were done according to United States Pharmaco-
poeia guidelines [4].
b Resolution was calculated for each two adjacent peaks.solutes increase according to the following order:
aliphatic < substituted benzenes < polyaromatic hydrocar-
bons [43]. In addition, the introduction of heteroatoms into the
aromatic rings has a pronounced enhancing effect on their p
activity [44]. Maleic acid is an aliphatic molecule, thus, it has
the lowest p activity and was eluted first, followed by LP
(substituted benzene), then TM (aromatic compound with
heteroatoms) and BM (polyaromatic hydrocarbon with het-
eroatoms) (Fig. 2).4.2. Method validation
The performance of the developed method was validated
following the ICH Guidelines [39]. Results of the statistical
analysis of the data [40] point out to the linearity of the
method (Table 1). In addition, the ICH Guidelines were used to
calculate the limit of detection and the limit of quantification
for the three studied drugs (Table 1).
Accuracy of the proposed method was also assessed. The
average percentages found and SD values were satisfactory. By
comparing the results obtained by the developed method with
those of the comparison HPLCmethods [30,36], the accuracy of
theproposedmethodwasconfirmedsince thecalculated tandF
valueswere lower than the tabulated ones [40], which indicated
no significant differences between the two methods regarding
the accuracy and precision, respectively. Results of intra- and
inter-day precision showed small values of percentage relative
standard deviation (%RSD) not exceeding 1.45%, confirming the
precision of the method (Table 2).
Selectivity of the method was confirmed by its ability to
separate the drugs in their binary mixtures with satisfactory
percentage found and small SD. Moreover, there were no in-
terferences from common excipients with the peaks of the
studied drugs or from maleic acid.
Deliberate minor variation in the optimum chromato-
graphic conditions did not significantly affect the NTP, Rs or T
of the chromatographic peaks, demonstrating the robustness
of the proposed method. The finally calculated system suit-
ability test parameters were satisfactory and within the
acceptance values (Table 3).
In comparison with the reported methods for TM/BM
mixture, the proposed method was 2 times more sensitive for
TM and 5, 2 and 2.5 times more sensitive for BM than the re-
ported HPLC methods [30,31,33, respectively]. While the
Table 4 e Application of the proposed and comparisonmethods for determination of the studied drugs in different dosage
forms.
Pharmaceutical preparationa Proposed method Comparison methods [30,36]
Conc. taken
(mg/mL)
% Foundb % Foundb
TM BM TM BM TM BM
Formulation A 17.0 5.0 100.96 98.66 100.19 98.20
34.0 10.0 99.28 101.01 101.11 100.10
68.0 20.0 100.12 99.83 102.15 99.55
Mean ± SD 100.12±0.84 99.83±1.18 101.15±0.98 99.28±0.98
tc 1.38 0.623
Fc 1.36 1.44
Nominal content (mg/mL) 6.808±0.06 1.997±0.02 6.878±0.07 1.986±0.02
TM LP TM LP TM LP
Formulation B 136.0 1.0 99.5 100.1 98.45 101.25
170.0 1.25 100.25 99.22 97.48 102.36
190.4 1.4 101.31 100.36 99.22 100.58
Mean ± SD 100.35±0.91 99.89±0.60 98.38±0.87 101.40±0.90
tc 2.708 2.412
Fc 1.088 2.264
Nominal content (mg/mL TM and mg/mL LP) 6.824±0.06 49.945±0.30 6.690±0.06 50.700±0.45
TM TM TM
Formulation C 17.0 98.32 98.77
34.0 101.26 98.04
68.0 99.79 100.04
Mean ± SD 99.79±1.47 98.95±1.01
tc 0.815
Fc 2.11
Nominal content (mg/mL) 6.786±0.10 6.729±0.07
BM BM BM
Formulation D 15.0 100.58 100.29
30.0 99.42 98.11
45.0 100.19 101.15
Mean ± SD 100.06±0.59 99.85±1.57
tc 0.221
Fc 7.05
Nominal content (mg/mL) 1.501±0.01 1.498±0.02
LP LP LP
Formulation E 1.0 98.07 97.55
1.5 98.56 98.05
2.0 99.01 100.45
Mean ± SD 98.55±0.47 98.68±1.55
tc 0.146
Fc 10.87
Nominal content (mg/mL) 49.275±.0.24 49.340±0.78
BM ¼ brimonidine tartrate; LP ¼ latanoprost; TM ¼ timilol maleate.
a Formulation A: Compigan eye drops (2 mg BT þ 6.8 mg/mL TM); Formulation B: Xalacom eye drops (50 mg LP þ 6.8 mg/mL TM); Formulation C:
Timolol eye drops (0.68% TM)l Formulation D: Alphagan eye drops (0.15% BT); Formulation E: Ioprost eye drops (50 mg/mL LP).
b Each result is the average of three independent determinations.
c Tabulated t and F values at p ¼ 0.05 are 2.776 and 19.00, respectively [40].
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and BM than the reported HPTLCmethod [35]. Although some
of the reported spectrophotometric [32,34] and HPLC [34]
methods exhibited comparable sensitivities for TM and BM,
these methods had narrow linearity ranges. Moreover, some
of the reported methods need some additional manipulation
steps such as column-temperature control [30] and wave-
length gradient [31,32], which may limit their widespread use
in routine quality control.Regarding the published literature for the determination of
TM/LP, the proposedmethod was 50 and 1.2 times more sensi-
tive for TM, and 2.5 and 3 times more sensitive for LP than the
publishedHPLCmethods [36,37, respectively]. Although there is
a reported HPLC method [38] for TM/LP mixture exhibiting
better sensitivity thanourmethod, the reported linearity ranges
for these compounds is narrow and does not practically permit
the determination of the two compounds simultaneously in
their coformulated eye drops. Also, the long retention times are
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Fig. 3 e Representative chromatograms for the determination of the three studied drugs in different ophthalmic solutions.
(A) BM (5.0 mg/mL) and TM (12.5 mg/mL) in Combigan eye drops; (B) LP (1.4 mg/mL) and TM (190.4 mg/mL) in Xalacom eye
drops. (C) TM (34.0 mg/mL) in Timolol eye drops; (D) BM (15.0 mg/mL) in Alphagan eye drops; (E) LP (25.0 mg/mL) in Ioprost eye
drops. BM ¼ brimonidine tartrate; LP ¼ latanoprost; TM ¼ timilol maleate.
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wavelength programming, and column-temperature control
are needed for most of these methods [37,38].
The present method is simpler, with no need for multistep
procedures like those mentioned earlier, and allowed the
determination of the two mixtures (TM/BM and TM/LP) with a
single simple procedure providing wide linearity ranges and
proper retention times.4.3. Pharmaceutical application
Commercially available coformulated and single-ingredient
ophthalmic solutions containing the studied drugs were suc-
cessfully analyzed. The obtained results indicated the appli-
cability of the proposedmethod for the routine quality control
of different ophthalmic solutions without interferences from
common excipients. This was evidenced by the calculated
j o u rn a l o f f o o d a nd d r u g an a l y s i s 2 4 ( 2 0 1 6 ) 4 4 1e4 4 9448values of the nominal contents which agreed well with the
contents claimed by the manufacturer as well as the small
values of SD (Table 4). It is worth noting that the method has
the ability to analyze TM and LP in such a challenging ratio
(136:1, respectively), with no need for complicated steps such
as wavelength programming.5. Conclusion
A simple, rapid, and accurate HPLC method was established
and validated for the separation and determination of three
commonly administered anti-glaucoma drugs (TM, BM and
LP) simultaneously. Chromatographic separation of the three
compounds was successfully achieved within a short analysis
time (< 6 minutes), offering a great advantage with respect to
quality control analysis. The proposedmethodwas applied for
the analysis of ophthalmic solutions containing two binary
mixtures of the studied drugs, TM/BM and TM/LP, in addition
to single-ingredient ophthalmic solutions containing these
compounds.Conflict of Interest
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